Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Infectious Diseases

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Prevalence of testosterone deficiency in HIV-infected men under antiretroviral therapy

  • Ana Rita Gomes1Email author,
  • Pedro Souteiro2,
  • Carolina Germana Silva1,
  • Bernardo Sousa-Pinto3, 4,
  • Francisco Almeida5,
  • António Sarmento5,
  • Davide Carvalho2, 6 and
  • Paula Freitas2, 6
BMC Infectious DiseasesBMC series – open, inclusive and trusted201616:628

https://doi.org/10.1186/s12879-016-1892-5

Received: 10 March 2016

Accepted: 1 October 2016

Published: 3 November 2016

Abstract

Background

The prevalence of hypogonadism in HIV-infected patients is still a matter of debate as there is no standardized consensual diagnostic method. In addition, the etiology and endocrine/metabolic implications of hypogonadism in this population remain controversial. This study aims to determine the prevalence of testosterone deficiency in a single-site hospital and to evaluate its association with potential risk factors, lipodystrophy, metabolic syndrome, and cardiovascular risk.

Methods

This study analyzed 245 HIV-infected men on combined antiretroviral therapy. Patients with low total testosterone (TT) levels (<2.8 ng/mL) and/or low calculated free testosterone (FT) levels (<6.5 ng/dL) were considered testosterone deficient. According to their LH and FSH levels, patients were classified as having hypogonadotropic or hypergonadotropic dysfunction. Other clinical, anthropometric, and analytic parameters were also collected and analyzed.

Results

The prevalence of testosterone deficiency in our population was 29.4 %. Among them, 56.9 % had hypogonadotropic dysfunction and 43.1 % presented with hypergonadotropic dysfunction. Patients with testosterone deficiency were older (p < 0.001), had higher HbA1c levels (p = 0.016) and higher systolic blood pressure (p = 0.007). Patients with lower testosterone levels had higher prevalence of isolated central fat accumulation (p = 0.015) and had higher median cardiovascular risk at 10 years as measured by the Framingham Risk Score (p = 0.004) and 10-Year ASCVD risk (p = 0.002).

Conclusions

The prevalence of testosterone deficiency in this HIV population is high, with hypogonadotropic dysfunction being responsible for the majority of cases. Testosterone deficiency might predispose to, or be involved, in the pathogenesis of HIV-associated lipodystrophy. Patients with low testosterone levels have higher cardiovascular risk, highlighting the importance of early diagnosis of this condition.

Keywords

HIV infectionHypogonadismLipodystrophyCardiovascular risk

Background

Several endocrine abnormalities, like hypogonadism, thyroid dysfunction, adrenal insufficiency, and diabetes were described as more prevalent in HIV patients in the pre-combined antiretroviral therapy (cART) era. They were mainly associated to HIV-related opportunistic infections and advanced multi-organ failure [13]. With the advent of highly active antiretroviral therapy in the 1990s, some of these metabolic diseases have waned but hypogonadism and diabetes remain frequent endocrinopathies in these patients [4].

Gonadal dysfunction leads to sexual impairment, bone and muscle mass loss, changes in body fat mass, fatigue, cognitive impairment, depressed mood and anemia, affecting the overall quality of life [1, 5, 6]. After assessing testosterone levels, additional tests are needed to determine whether hypogonadism is primary (hypergonadotropic), or secondary (hypogonadotropic) [1, 7]. According to previous studies in this population, hypogonadotropic dysfunction is responsible for the majority of cases, while primary disease is seen less frequently (occasionally, patients may have a combination of both). [8]. Overall, the causes of testosterone deficiency among HIV-infected men remain controversial, and there is lack of studies concerning the etiology and metabolic and endocrine consequences of this condition [1]. Additionally, the prevalence of testosterone deficiency in the HIV population is not well defined, ranging from 16 to 54 %, as slightly different criteria are adopted in different studies [4, 6, 9].

Therefore, this study aims to determine the prevalence of testosterone deficiency in a population of HIV-infected men under cART, as well as the prevalence of hypo- and hypergonadotropic dysfunction. Additionally, it aims to assess the association between testosterone deficiency and potential risk factors, and to evaluate the relationship between lower testosterone levels, lipodystrophy, metabolic syndrome and cardiovascular risk.

Methods

Subjects

Two-hundred and forty five adult men with serologically documented HIV infection on cART were evaluated at the Endocrinology Outpatient Department of Centro Hospitalar São João (a tertiary center in Northern Portugal). Patients were consecutively referred from the Infectious Diseases Clinic between January/2008 to December/2014, and were enrolled in the first visit.

Patients with acute or severe illness, previous treatment with androgen-derived agents and concurrent endocrinopathy (e.g. uncontrolled hypothyroidism, adrenal insufficiency, hyperprolactinemia, known pituitary disease) were excluded.

Clinical assessment

For all patients, the following information was collected, using a standardized protocol: age, time since HIV diagnosis, risk factor for HIV transmission, type and duration of cART exposure, CD4+ count, plasmatic HIV RNA load, smoking history (current, past, or never) and alcohol consumption (yes or no). HIV stages were defined using the Centers for Disease Control and Prevention’s (CDC) classification into asymptomatic (A), symptomatic (B) and AIDS (C) [10].

Height was measured in the standing position, using a wall stadiometer (Holtain Limited Crymych, Dyfed®), and body weight was measured using the TANITA (Tanita®, model TBF 300) scale. Circumferences of neck, waist, hip, thigh and arm were measured, as previously described, and blood pressure (BP) was measured using the current recommendations [11, 12].

Clinical lipodystrophy was assessed by both patient and practitioner, and was defined as peripheral lipoatrophy, with or without central fat accumulation [12]. Abdominal prominence (central obesity) was defined by a waist circumference >102 cm, as defined by NCEP-ATP III modified criteria for metabolic syndrome [13]. All clinical assessments were performed by the same observer. Patients were classified into four different groups: (1) No lipodystrophy (patients without clinical lipoatrophy and without abdominal prominence); (2) Isolated central fat accumulation (patients without clinical lipoatrophy and with abdominal prominence); (3) Isolated lipoatrophy (patients with clinical lipoatrophy and without abdominal prominence), and; (4) Mixed forms of lipodystrophy (patients with clinical lipoatrophy and with abdominal prominence) [11].

Laboratory analysis

An early morning venous blood sample was taken after a 12-hour overnight fast. All samples were analyzed at the central laboratory of our hospital. Total testosterone (TT), sex hormone binding globulin (SHBG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were determined using Cobas e411 (Roche Diagnostic). Glycosylated hemoglobin (HbA1c) was measured by Variant II Turbo (Bio-Rad). To evaluate lipid profile, we measured total cholesterol, LDL cholesterol (LDL-C), HDL cholesterol (HDL-C) and triglycerides levels, using Olympus AU5400 (BecKman Coulter). The CD4+ cell count (×106 cell/L) and plasma HIV RNA loads were assessed by flow cytometry and by a quantitative reverse transcriptase polymerase chain reaction (Roche Diagnostic), respectively.

Criteria for the definition of gonadal status

Testosterone deficiency was defined based on a serum total testosterone (TT) below 2.8 ng/mL and/or a calculated free testosterone levels (FT), according to Vermeulen formula, below 6.5 pg/mL [14].

According to the normal ranges for serum LH and FSH, as defined by our central laboratory (1.7–8.3 mUI/mL and 1.5–12.4 mUI/mL, respectively), patients were assigned as having hypogonadotropic (low or normal LH and/ or FSH) or hypergonadotropic dysfunction (high LH and/ or FSH). Patients were classified as having high sex hormone-binding globulin (SHBG) according to the threshold value of 48.4 nmol/L.

Metabolic syndrome definition and cardiovascular risk scores

We defined Metabolic Syndrome (MS) according to the modified NCEP-ATP III criteria, requiring the presence of three of the following risk factors: (1) elevated waist circumference (>102 cm); (2) elevated triglycerides (≥150 ml/dL or specific treatment); (3) reduced HDL-C levels (<40 mg/dL), (4) elevated blood pressure (>130/85 mmHg or treatment with anti-hypertensive drugs), and; (5) elevated fasting glucose (≥100 mg/dL or use of glucose-lowering drugs) [13].

The cardiovascular disease (CVD) risk at 10 years was measured by the Framingham Risk Score (FRS), using a sex-specific algorithm that incorporates age, treated, and untreated systolic blood pressure, HDL-C, total cholesterol, glucose, and smoking status [15]. Based on the Adult Treatment Panel III (ATP III) guidelines, individuals were stratified into four risk categories: (1) Low risk (0–1 CVD risk factors); (2) moderate risk (≥2 CVD risk factors and a 10-year CVD risk <10 %); (3) moderately high risk (≥2 CVD risk factors and a 10-year CVD risk 10–20 %), and; (4) high risk (CHD or CHD equivalent or ≥2 CVD risk factors and a 10-year CVD risk >20 %) [16].

The 10-year and lifetime atherosclerotic cardiovascular disease (ASCVD) risk scores were calculated based on the American College of Cardiology (ACC)/ American Heart Association’s (AHA) guidelines. For all patients, we used a sex, ethnic group and age-specific multivariable risk factor algorithm that incorporates total cholesterol, HDL-C, untreated systolic blood pressure, diabetes history, and smoking status [17].

Statistical analysis

Categorical variables were presented as absolute frequencies and percentages, and were analyzed using Chi-square or Fisher’s exact test. Continuous variables were presented as medians and interquartile ranges, and were analyzed using the Mann–Whitney U test. P values <0.05 were considered to be statistically significant. All statistical analysis was performed using SPSS version 22.0 (SPSS, Inc., Chicago, IL).

Results

A total of 245 HIV-infected males on cART were evaluated, and 29.4 % were found to have testosterone deficiency, with a median of TT and calculated FT of 2.6 ng/mL and 5.2 ng/dL, respectively. Among the patients with reduced TT, 50 % had high SHBG levels.

In the group of patients with testosterone deficiency, 56.9 % had hypogonadotropic and 43.1 % had hypergonadotropic dysfunction. When different clinical, anthropometric and analytic variables were analyzed regarding these two categories of testosterone deficiency, patients with elevated gonadotrophins presented a higher frequency of NRTI use (100 % vs. 86.7 %; p = 0.028) and lower CD4+ counts (336.0 vs. 449.0; p = 0.030). No other differences were found between the two groups of patients.

The baseline characteristics of our study population are shown in Table 1. Patients with testosterone deficiency were older than the remainder (median age of 51.5 versus 48.0 years; p < 0.001). No significant differences were observed regarding the risk factors for HIV transmission, stages of CDC criteria, length of HIV infection, and cART, CD4+, viral count, viral suppression, and class of antiretroviral drugs used.
Table 1

Participants baseline characteristics, according to the presence of testosterone deficiency

 

Total

(n = 245)

Testosterone deficiency

(n = 72)

Without testosterone deficiency

(n = 173)

p value

Age [years, median (IQR)]

48.0 (15.0)

51.5 (11.8)

48.0 (7.3)

<0.001a

Duration of HIV infection [years, median (IQR)]

8.0 (6.0)

6.0 (8.0)

8.0 (6.0)

0.567a

HIV stage [n (%)]d

 A

122 (52.1)

31 (44.9)

91 (55.2)

0.157b

 B

12 (5.1)

6 (8.7)

6 (3.6)

 

 C

100 (42.7)

32 (46.4)

68 (41.2)

 

cART [years, median (IQR)]

6.0 (7.0)

4.5 (8.8)

7.0 (6.0)

0.447a

NRTI [n (%)]

213 (86.9)

67 (31.5)

146 (84.4)

0.067c

NNRTI [n (%)]

104 (42.4)

33 (45.8)

71 (41.0)

0.489b

PI [n (%)]

119 (48.6)

33 (45.8)

86 (49.7)

0.580b

FI [n (%)]

1 (0.4)

0

1 (0.6)

0.999c

II [n (%)]

16 (6.5)

6 (8.3)

10 (5.8)

0.570c

Viral load (<50) [n (%)]

131 (82.4)

33 (76.7)

98 (84.5)

0.255b

CD4 count [cells/mm3, median (IQR)]

477.0 (327.3)

501.0 (351.5)

526.5 (286.8)

0.157a

HIV risk factor [n (%)]

 Injecting drug user

55 (23.7)

18 (26.5)

37 (22.6)

0.561b

 Heterosexual contact

118 (50.9)

37 (54.4)

81 (49.4)

 

 Homosexual contact

50 (21.6)

11 (16.2)

39 (23.8)

 

 Others

9 (3.9)

2 (2.9)

7 (4.3)

 

cART combined antiretroviral therapy, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, FI fusion inhibitor, II integrase inhibitor

aMann-Whitney U test; bChi-square test, cFisher test; dInformation only available for 234 patients

Table 2 shows the clinical characteristics of the population studied. Patients with testosterone deficiency had a significantly higher median waist circumference (99.5 cm versus 93.0 cm; p = 0.030). Lower testosterone individuals also presented a higher median HbA1c percentage (5.5 % versus 5.3 %; p = 0.016) and a higher median systolic blood pressure (133.5 mmHg versus 130.0 mmHg; p = 0.007). There were no significant differences between the two groups concerning weight, lipid profile, neck, upper-arm, abdominal, and hip circumferences, smoking status, alcohol consumption and frequency of metabolic syndrome. When patients were stratified into four groups of fat distribution (presence or not of clinical lipoatrophy and abdominal prominence), patients with lower testosterone levels had a higher percentage of isolated central fat accumulation (18.1 % vs. 7.5 %; p = 0.015).
Table 2

Participants clinical characteristics according to the presence of testosterone deficiency

 

Testosterone deficiency

(n = 72)

Without testosterone deficiency

(n = 173)

p value

Weight [kg, median (IQR)]

76.3 (25.9)

71.3 (16.2)

0.857a

Height [cm, median (IQR)]

171.0 (8.0)

169.0 (7.5)

0.204a

BMI [(kg/m2), median (IQR)]

26.5 (16.8)

25.2 (5.4)

0.160a

 Underweight [n (%)]

5 (7.0)

6 (3.6)

0.028b/0.155c

 Normal weight [n (%)]

26 (36.3)

78 (46.2)

 

 Overweight [n (%)]

23 (32.4)

67 (39.6)

 

 Obesity [n (%)]

17 (23.9)

18 (10.7)

 

Neck circumference [cm, median (IQR)]

40.0 (4.8)

39.0 (3.0)

0.196a

Upper-arm circumference [cm, median (IQR)]

28.3 (3.8)

28.0 (3.8)

0.197a

Abdominal circumference [cm, median (IQR)]

98.0 (13.8)

93.0 (8.6)

0.492a

Waist circumference [cm, median (IQR)]

99.5 (19.8)

93.0 (13.5)

0.030a

Hip circumference [cm, median (IQR)]

47.0 (6.0)

47.5 (6.0)

0.906a

Metabolic syndrome [n (%)]

33 (45.8)

69 (39.9)

0.390b

Blood pressure [n (%)]

30 (41.7)

69 (40.1 %)

0.822b

 Systolic blood pressure [median (IQR)]

133.5 (40.0)

130.0 (30.0)

0.007a

 Diastolic blood pressure [median (IQR)]

79.0 (25.0)

80.0 (15.0)

0.756a

Smoking history [n (%)]

 Current

21 (30.4)

72 (42.6)

0.127b

 Former

25 (36.2)

42 (24.9)

 

 Never

23 (33.3)

55 (32.5)

 

Alcohol consumption [n (%)]

41 (59.4)

77 (45.6)

0.052b

Total cholesterol [mg/dL, median (IQR)]

210.0 (69.0)

221.0 (70.5)

0.668a

LDL cholesterol [mg/dL, median (IQR)]

129.0 (37.0)

129.0 (72.8)

0.573a

HDL cholesterol [mg/dL, median (IQR)]

43.5 (13.3)

42.5 (13.3)

0.125a

Triglycerides [mg/dL, median (IQR)]

215.0 (215.3)

218.0 (162.0)

0.631a

HbA1c [%, median (IQR)]

5.5 (1.7)

5.3 (1.0)

0.016a

Total testosterone [ng/mL, median (IQR)]

2.6 (2.6)

5.9 (2.7)

<0.001a

Free testosterone [ng/dL, median (IQR)]

5.2 (1.5)

9.1 (3.6)

<0.001a

SHBG [nmol/L, median (IQR)]

35.2 (44.6)

46.6 (29.6)

0.083a

LH [mIU/mL, median (IQR)]

5.0 (4.9)

5.2 (3.2)

0.001a

FSH [mIU/mL, median (IQR)]

6.7 (7.1)

5.1 (4.1)

<0.001a

FRS [median (IQR)]

13.0 (5.0)

12.0 (6.0)

0.004a

 <10 [n (%)]

16 (22.2)

66 (38.2)

0.008b/0.003c

 10–20 [n (%)]

48 (66.7)

101 (58.4)

 

 >20 [n (%)]

8 (11.1)

6 (3.5)

 

10-Year ASCVD risk [%, median (IQR)]

7.1 (6.5)

6.8 (8.3)

0.002a

Lifetime ASCVD risk [n (%)]

 <40 %

4 (10.0)

11 (8.0)

0.789b

 40–50 %

22 (55.0)

84 (60.9)

 

 >50 %

14 (35.0)

43 (31.2)

 

Lipodistrophy [n (%)]

39 (56.5)

96 (58.5)

0.776b

Waist circumference (>102 cm) [n(%)]

23 (31.9)

30 (17.3)

0.011b

No lipodystrophy [n (%)]

20 (27.8)

59 (34.3)

0.321b

Isolated central fat accumulation [n (%)]

13 (18.1)

13 (7.5)

0.015b

Isolated lipoatrophy [n (%)]

29 (40.3)

83 (48.3)

0.254b

Mixed forms of lipodystrophy [n (%)]

10 (13.9)

17 (9.8)

0.355b

BMI body mass index, LDL low density lipoprotein, HDL high density lipoprotein, HbA1c glycosylated hemoglobin, SHBG sex hormone binding globulin, LH luteinizing hormone, FSH follicle stimulating hormone, FRS Framingham risk score, ASCVD atherosclerotic cardiovascular disease

aMann-Whitney U test; bChi-square test; cLinear by linear association test

Patients with testosterone deficiency had a significantly higher risk of CVD at 10 years, as measured by the FRS (median score of 13.0 and 12.0; p = 0.004). Those patients also presented a significantly higher 10-Year risk of CVD with the ASCVD risk score (7.1 versus 6.8; p = 0.002), although no significant differences were found concerning lifetime ASCVD risk (p = 0.789).

Discussion

The introduction of cART has led to a decreased prevalence of hypogonadism among HIV-infected men. This change is probably related to the reduced frequency of end-stage AIDS, opportunistic infections, chronic immune activation and HIV-associated wasting syndrome. However, hypogonadism remains an important problem in HIV-infected patients, where higher rates of this condition are found compared to the general population, even in patients with early stages of the disease [1, 18]. As previously mentioned, the prevalence of hypogonadism in this population is still a matter of debate, ranging from 16 to 54 % in different reports [4, 6, 9]. This discrepancy might be due to a lack of standardized, validated methods for its assessment, and to a lack of universal agreement in a clinical and/or biochemical definition for hypogonadism [19]. In our study, we obtained a prevalence of testosterone deficiency of 29.4 % in a population of 245 HIV-infected men on cART. It has been recognized that testosterone levels may be difficult to interpret in HIV-infected patients, as they tend to have a higher concentration of SHBG, which may increase TT values [1, 18, 20]. Therefore, following the recommendations to use FT levels in individuals with HIV infection, we used TT and FT calculated by the Vermeulen formula to define testosterone deficiency, in order to avoid false negatives that would possible occur if only TT levels had been used. Accordingly, if only serum TT had been used, some patients with low testosterone levels would have been missed as 50 % of them had high SHBG levels [14, 21].

Regarding the categories of testosterone deficiency, our results shows that hypogonadotropic dysfunction was responsible for the majority of cases. This is in accordance with several studies that report a progressive change in the etiology of testosterone deficiency in HIV-infected patients. Publications in the pre-cART era reported higher prevalences of gonadal dysfunction caused by direct involvement by the virus with a reduction in the Leydig cell number [22]. Recent investigations, after the appearance of more effective therapy, showed a relatively higher preponderance of secondary dysfunction [6]. Several different mechanisms have been suggested to explain the effect on the hypothalamic-pituitary-gonadal (HPG) axis, including poor health status, undernutrition, frailty, anti-retroviral drugs, the virus per se, opportunistic infections and increased visceral adiposity [8].

Consistently with other studies, the presented data shows that the prevalence of testosterone deficiency increases with age, as it happens in the general population However, there was no significant impact of the HIV transmission risk factor and sexual orientation on testosterone levels, confirming the findings of other groups [1]. With regards to the antiretroviral agents, our study did not find any difference between patients with low testosterone levels and the remaining ones among the five studied pharmacologic groups. In fact, previous studies show conflicting results in this area [1, 7, 18].

We have shown that 18.1 % of patients with testosterone deficiency presented visceral obesity (as measured by waist circumference >102 cm), contrasting to 7.5 % of eugonadal individuals. The lipodystrophy syndrome, which has a reported prevalence of 41 % in HIV-infected patients, is a well-known adverse effect of cART. It comprises fat redistribution abnormalities, insulin resistance and dyslipidemia [7, 23]. However, the impact of cART on the HPG axis is still not completely understood, and little is known about the influence of sex hormone levels on the development of lipodystrophy [23]. Testosterone is one of the major determinants of regional distribution of fat and body composition, favoring the accumulation of visceral fat. The underlying pathophysiological mechanisms include an increase in tissue sensitivity to glucocorticoids, reduction of adipokines, and a reduction of peroxisome proliferator-activated receptor (PPAR-γ) activity [24]. Testosterone role in insulin sensitivity in HIV-lipodystrophy has also been proposed since several studies have shown that low levels of serum testosterone correlate not only with central fat accumulation but also with higher insulin levels [7].

HIV-infected patients also present an increased cardiovascular risk when compared with the general population. The pathogenesis of CVD in these patients is complex, and several factors appear to be involved, including androgen dysfunction [7, 25]. Low testosterone levels are independently associated with cardiovascular risk and are independent predictors of mortality [19, 26]. Accordingly, in our study, HIV patients with lower testosterone levels had a significantly higher 10-year risk of coronary heart disease, as measured by the FRS and 10-Year ASCVD. We could hypothesize that men with testosterone deficiency, besides being older, are at additional CV risk due to the higher frequency of hyperglycemia, abdominal obesity and hypertension as described in our results. Regan et al. compared the proportion of HIV patients with high predicted 10-year CVD risk using the FRS versus the ASCVD risk prediction algorithm [27]. The authors reported that the ASCVD algorithm classified a larger proportion of HIV patients as high-risk, compared to the FRS. This is consistent with our results, since a higher percentage of individuals were classified as having a high-risk by the ASCVD algorithm, independently of their testosterone status. Nevertheless, no significant differences were found in the lifetime risk of cardiovascular disease. This discrepancy can possibly be explained by the fact that only patients aged between 20 and 59 years-old could be included in this score. Regardless, we should mention that both the FRS and ASCVD appear to underestimate the actual risk of events, as reported by Thompson-Paul et al. [28]. Therefore, risk assessment remains reliant on the use of traditional risk factors, despite their inherent limitations. To better estimate CVD risk, different models including additional HIV-specific risk factors, such as immunologic or virologic status, may need to be considered [25, 28]. Incorporation of imaging studies assessing subclinical atherosclerosis in risk algorithms for HIV patients may add useful information in the future [25].

This study has some limitations that are inherent to the observational design and the cross-sectional nature of our analyses. In addition, patients with testosterone deficiency diagnosed prior to HIV infection were not excluded. Consequently, conclusions regarding causality cannot be made with certainty. Although we have included all patients referred to our department, bias in the referral cannot be excluded, since some patients could have been referred because they already had testosterone deficiency or metabolic disorders related to cART. Therefore, we might have selected a study population where metabolic and endocrine complications were over-represented.

Our study has some strong points, including the fact that the study was performed in a highly experienced unit in the assessment of metabolic and body fat abnormalities in HIV-infected patients, with all clinical assessments being performed by the same investigator. Finally, another positive point was the fact that our sample size was relatively large when compared to other studies performed in this area.

Conclusions

The prevalence of testosterone deficiency in HIV-infected men is high, with hypogonadotropic dysfunction being responsible for the majority of cases. Patients with lower testosterone levels were older, had poorer glycemic control, higher systolic blood pressure and increased waist circumference. Our results corroborate the hypothesis that testosterone deficiency may predispose or might be involved in the pathogenesis of HIV-associated lipodystrophy. This has a significant clinical impact, since both conditions are common in this population and are associated with a negative impact on the quality of life and with poor adhesion to therapy. Additionally, this study suggests that patients with lower testosterone levels have higher cardiovascular risk scores, highlighting the importance of early diagnosis of this condition.

Abbreviations

ACC: 

American college of cardiology

AHA: 

American heart association

AIDS: 

Acquired Immune Deficiency Syndrome

ASCVD: 

Atherosclerotic cardiovascular disease

BMI: 

Body mass index

cART: 

Combined antiretroviral therapy

CDC: 

Centers for Disease Control and Prevention

FI: 

Fusion inhibitor

FRS: 

Framingham risk score

FSH: 

Follicle stimulating hormone

FT: 

Free testosterone

HbA1c: 

Glycosylated hemoglobin

HDL: 

High density lipoprotein

HIV: 

Human immunodeficiency virus

HPG: 

Hypothalamic-pituitary-gonadal

IDF: 

International diabetes federation

II: 

Integrase inhibitor

LDL: 

Low density lipoprotein

LH: 

Luteinizing hormone

MS: 

Metabolic syndrome

NNRTI: 

Non-nucleoside reverse transcriptase inhibitor

NRTI: 

Nucleoside reverse transcriptase inhibitor

PI: 

Protease inhibitor

SHBG: 

Sex hormone binding globulin

TT: 

Total testosterone

Declarations

Funding

The authors declare that they received no funding to conduct this study.

Availability of data and materials

The data that support the findings of this study are available on request from the corresponding author [ARG]. The data are not publicly available because they contain information that could compromise research participant privacy/consent.

Authors’ contributions

ARG conceived the study, participated in its design, in the acquisition of data and drafted the manuscript; PS participated in the acquisition of data and in the manuscript revision; FA participated in the acquisition of data; BSP performed the statistical analysis and revised critically the manuscript; CGS and PF participated in its design and revised critically the manuscript; AS and DC revised critically the manuscript; All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

All patients provided written informed consent and the study protocol was approved by the São João Hospital’s Ethics Committee for Health.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Faculty of Medicine, University of Porto
(2)
Endocrinology, Diabetes and Metabolism Department, Centro Hospitalar São João
(3)
Department of Health Information and Decision Sciences, Faculty of Medicine (CIDES), University of Porto
(4)
Center for Health Technology and Services Research (CINTESIS), Faculty of Medicine, University of Porto
(5)
Infectious Diseases Department, Centro Hospitalar São João, Faculty of Medicine, University of Porto
(6)
Faculty of Medicine, i3S - Instituto de Investigação e Inovação em Saúde, University of Porto

References

  1. Crum NF, Furtek KJ, Olson PE, Amling CL, Wallace MR. A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDS. 2005;19:655–71.View ArticlePubMedGoogle Scholar
  2. Unachukwu C, Uchenna D, Young E. Endocrine and metabolic disorders associated with human immune deficiency virus infection. West Afr J Med. 2009;28:3–9.PubMedGoogle Scholar
  3. Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev. 1996;17:518–32. The Endocrine Society.PubMedGoogle Scholar
  4. Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, Diazzi C, et al. Premature decline of serum total testosterone in HIV-infected men in the HAART-Era. PLoS One. 2011;6.Google Scholar
  5. Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, et al. Testosterone Replacement and Resistance Exercise in HIV-Infected Men With Weight Loss and Low Testosterone Levels. JAMA. 2000;283:763–70.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Klein RS, Lo Y, Santoro N, Dobs AS. Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis. 2005;41:1794–803.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Ashby J, Goldmeier D, Sadeghi-Nejad H. Hypogonadism in human immunodeficiency virus-positive men. Korean J Urol. 2014;55:9–16.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Rochira V, Guaraldi G. Hypogonadism in the HIV-Infected Man. Endocrinol Metab Clin North Am. 2014;43:709–30. Elsevier Inc.View ArticlePubMedGoogle Scholar
  9. Crum-Cianflone NF, Bavaro M, Hale B, Amling C, Truett A, Brandt C, et al. Erectile dysfunction and hypogonadism among men with HIV. AIDS Patient Care STDS. 2007;21:9–19.View ArticlePubMedGoogle Scholar
  10. Castro KG, Ward JW, Slutsker L, Buehler JW, Jaffe HW, Berkelman RL, et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Report, Natl Cent Infect Dis Div HIV/AIDS, Centers Dis Control Prev. 1992;41:1–19.Google Scholar
  11. Freitas P, Carvalho D, Santos AC, Mesquita J, Matos MJ, Madureira AJ, et al. Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance. BMC Infect Dis. 2012;12:180.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Freitas P, Carvalho D, Santos AC, Mesquita J, Correia F, Xerinda S, et al. Assessment of body fat composition disturbances by bioimpedance analysis in HIV-infected adults. J Endocrinol Invest. 2011;34:321–9.Google Scholar
  13. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143.Google Scholar
  14. Vermeulen A, Verdonck L, Kaufman JM. A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum. J Clin Endocrinol Metab. 1999;84:3666–72.View ArticlePubMedGoogle Scholar
  15. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: The Framingham heart study. Circulation. 2008;117:743–53.View ArticlePubMedGoogle Scholar
  16. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.View ArticlePubMedGoogle Scholar
  17. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2013;2014:129.Google Scholar
  18. Cotter AG, Powderly WG. Endocrine complications of human immunodeficiency virus infection: Hypogonadism, bone disease and tenofovir-related toxicity. Best Pract Res Clin Endocrinol Metab. 2011;25:501–15. Elsevier Ltd.View ArticlePubMedGoogle Scholar
  19. Potenza M, Shimshi M. Male hypogonadism: The unrecognized cardiovascular risk factor. J Clin Lipidol. 2008;2:71–8.View ArticlePubMedGoogle Scholar
  20. Antonio L, Wu FCW, O’Neill TW, Pye SR, Ahern TB, Laurent MR, et al. Low Free Testosterone is Associated with Hypogonadal Signs and Symptoms in Men with Normal Total Testosterone. J Clin Endocrinol Metab. 2016;101(7):2647–57Google Scholar
  21. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in Men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–59. The Endocrine Society.View ArticlePubMedGoogle Scholar
  22. De Paepe ME, Vuletin JC, Lee MH, Rojas-Corona RR, Waxman M. Testicular atrophy in homosexual AIDS patients: An immune-mediated phenomenon? Hum Pathol Elsevier. 2016;20:572–8.View ArticleGoogle Scholar
  23. Wunder DM, Fux CA, Bersinger NA, Mueller NJ, Hirschel B, Cavassini M, et al. Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: A case-control study. HIV Med. 2008;9:427–32.View ArticlePubMedGoogle Scholar
  24. Bhasin S, Parker RA, Sattler F, Haubrich R, Alston B, Umbleja T, et al. Effects of testosterone supplementation on whole body and regional Fat mass and distribution in human immunodeficiency virus-infected Men with abdominal obesity. J Clin Endocrinol Metab. 2007;92:1049–57. The Endocrine Society.View ArticlePubMedGoogle Scholar
  25. Shahbaz S, Manicardi M, Guaraldi G, Raggi P. Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk? World J Cardiol. 2015;7:633–44.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011;165:687–701.View ArticlePubMedGoogle Scholar
  27. Regan S, Meigs JB, Massaro J, Agostino RBD, Grinspoon SK, Triant VA, et al. Evaluation of the ACC / AHA CVD Risk Prediction Algorithm Among HIV-Infected Patients Contact . CROI Conf. 2009Google Scholar
  28. Angela M. Thompson-Paul, Lichtenstein KA, Armon C, Buchacz K, Debes R, Chmiel JS, et al. Cardiovascular Disease Risk Prediction in the HIV Outpatient Study (HOPS). CROI Conf. 2015.Google Scholar

Copyright

© The Author(s). 2016

Advertisement